DrugBiological
Ligelizumab clinical trials
Also written QGE031.
- studies test it
- 19
- open now
- 0
- in phase 3
- 7
- first study started
- 2011
How studies write it
Studies that test it under each name
Name
Development codes
- QGE031
- 14
Studies by the year they started
18 studies that test it; most in 2012 (3)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2012 | 3 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 1 |
| 2018 | 3 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 2 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 10
- Phase 3
- 7
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 19 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses ligelizumab is read from its arms, and is right about nine times in ten.
Testing it · 19
- Study to Investigate the Efficacy and Safety of QGE031 in Adolescent Patients With Chronic Spontaneous Urticaria (CSU)CompletedPhase 2Novartis PharmaceuticalsNCT03437278Written as Ligelizumab
- Long-term Extension Study of Ligelizumab in Food AllergyTerminatedPhase 3Novartis PharmaceuticalsNCT05678959Written as Ligelizumab 120 mg
- Efficacy and Safety of QGE031 (Ligelizumab) in Patients With Peanut AllergyTerminatedPhase 3Novartis PharmaceuticalsNCT04984876Written as ligelizumab
- A Safety and Efficacy Study of Ligelizumab in the Treatment of CSU in Japanese Patients Inadequately Controlled With H1- AntihistaminesCompletedPhase 3Novartis PharmaceuticalsNCT03907878Written as Ligelizumab
- A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.CompletedPhase 3Novartis PharmaceuticalsNCT03580356Written as Ligelizumab
- Study of Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria Patients Who Completed a Previous Study With LigelizumabTerminatedPhase 3Novartis PharmaceuticalsNCT04210843Written as Ligelizumab
- Study of Mechanism of Action of Ligelizumab (QGE031) in Patients With Chronic UrticariaTerminatedPhase 1Novartis PharmaceuticalsNCT04513548Written as Ligelizumab
- Study of Efficacy and Safety of Ligelizumab in Adolescents and Adults With Chronic Inducible Urticaria Who Remain Symptomatic Despite Treatment With H1- AntihistaminesTerminatedPhase 3Novartis PharmaceuticalsNCT05024058Written as Ligelizumab
- A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistaminesCompletedPhase 3Novartis PharmaceuticalsNCT03580369Written as Ligelizumab
- A Safety Extension Study to Evaluate the Long-term Safety of QGE031 in Chronic Spontaneous Urticaria (CSU) PatientsCompletedPhase 2Novartis PharmaceuticalsNCT02649218Written as Ligelizumab
- Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSUCompletedPhase 2Novartis PharmaceuticalsNCT02477332Written as QGE031
- Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With AsthmaCompletedPhase 2Novartis PharmaceuticalsNCT01716754Written as QGE031
- Efficacy and Safety of QGE031 Compared With Placebo in Patients Aged 18-75 Years With AsthmaTerminatedPhase 2Novartis PharmaceuticalsNCT02336425Written as QGE031
- Long-term Safety Study of QGE031 in Patients With Allergic Asthma Who Completed Study CQGE031B2201TerminatedPhase 2Novartis PharmaceuticalsNCT02075008Written as QGE031
- A Study Evaluating the Safety and Efficacy of QGE031 in Atopic Dermatitis PatientsCompletedPhase 2Novartis PharmaceuticalsNCT01552629Written as QGE031
- Safety, Efficacy and PK/PD of QGE031 vs. Placebo in Patients With Active Bullous Pemphigoid Despite Oral Steroid TreatmentTerminatedPhase 2Novartis PharmaceuticalsNCT01688882Written as QGE031
- A Study Evaluating the Efficacy of QGE031 Compared to Omalizumab in Patients With Allergic AsthmaCompletedPhase 1/2Novartis PharmaceuticalsNCT01703312Written as QGE031
- Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of QGE031 in Japanese Atopic Male SubjectsCompletedPhase 1Novartis PharmaceuticalsNCT01596712Written as QGE031
- Efficacy and Safety of 4 Doses of QGE031 in Patients 18-50 Years of Age With Peanut AllergyWithdrawnPhase 2Novartis PharmaceuticalsNCT01451450Written as QGE031
Codes
What other systems call ligelizumab · ClinicalTrials.gg INT000247
- MeSH (NLM) C000598891ligelizumabOne source NLM
- UNII (FDA) L8LE0L691TLIGELIZUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q6545898LigelizumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C175809LigelizumabOne source FDA
- DrugBank DB11856One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000598891 | ligelizumab | One source NLM |
| UNII (FDA) | L8LE0L691T | LIGELIZUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q6545898 | Ligelizumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C175809 | Ligelizumab | One source FDA |
| DrugBank | DB11856 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.